Evidence map›Paper›PMID 37559881›Full record

ArticleMolecular and clinical oncology2023

Secondary leiomyosarcoma of the nasal cavity in a treated patient with possible hereditary retinoblastoma with germline reciprocal translocation of RB1 and DMXL1 and somatic TP53 mutation: A case report.

Toshinari Yagi, Harumi Nakamura, Yoji Kukita, Toru Wakamatsu, Hironari Tamiya, Shou Nakai, Makiyo Watanabe, Shigeki Kakunaga, Haruna Takami, Rie Suzuki and 2 more

Abstract readCase Reports
In one paragraph

Article in Molecular and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Toshinari YagiDepartment of Outpatient Chemotherapy, Osaka International Cancer Institute, Osaka, Osaka 541-8567, Japan.
Harumi NakamuraLaboratory of Genomic Pathology, Osaka International Cancer Institute, Osaka, Osaka 541-8567, Japan.
Yoji KukitaLaboratory of Genomic Pathology, Osaka International Cancer Institute, Osaka, Osaka 541-8567, Japan.
Toru WakamatsuDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka, Osaka 541-8567, Japan.
Hironari TamiyaDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka, Osaka 541-8567, Japan.
Shou NakaiDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka, Osaka 541-8567, Japan.
Makiyo WatanabeDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka, Osaka 541-8567, Japan.
Shigeki KakunagaDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka, Osaka 541-8567, Japan.
Haruna TakamiDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka, Osaka 541-8567, Japan.
Rie SuzukiDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka, Osaka 541-8567, Japan.
Satoshi TakenakaDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka, Osaka 541-8567, Japan.
Yoshiko HashiiDepartment of Pediatrics, Osaka International Cancer Institute, Osaka, Osaka 541-8567, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Retinoblastoma is a common primary intraocular malignant tumor that affects infants and young children. Radiation therapy for hereditary retinoblastoma increases the risk of secondary malignancy. The present report discusses the case of a retinoblastoma survivor who developed secondary leiomyosarcoma 42 years after receiving radiation therapy. The retinoblastoma of the patient was unilateral, and the patient had no family history of the disease. RNA and DNA panel sequencing of the leiomyosarcoma tissue was performed to elucidate the molecular mechanism of this secondary malignancy. The RNA panel sequencing detected a germline reciprocal translocation of RB1 and DMXL1, leading to a diagnosis of possible hereditary retinoblastoma. Furthermore, it detected a somatic fusion gene (RAD51-KNL1). The DNA panel sequencing identified various germline or somatic variants, including a somatic splice acceptor site mutation of TP53. We hypothesized that the molecular mechanism of the secondary malignancy of this patient was the combination of a germline reciprocal translocation of RB1 and DMXL1 and the accumulation of various somatic mutations containing the splice acceptor site mutation of TP53, which ultimately led to the development of a secondary leiomyosarcoma. Further prospective investigations are necessary to fully understand the role of reciprocal translocation of RB1 and DMXL1 or other mutations in the tumorigenesis of second malignancies in patients with hereditary retinoblastoma.

Indexed as

DMXL1leiomyosarcomaRB1retinoblastomaTP53

Identifiers

PMID37559881
PMCPMC10407467

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.